RVMDW
Revolution Medicines, Inc. Warrant
NASDAQ · Healthcare · Biotechnology · US
$11.89
−0.79%Sep 2, 2026, 21:50 UTC
Revolution Medicines announced that The New England Journal of Medicine published Phase 1/2 clinical data on its drug RASONQUE (daraxonrasib) for metastatic non-small cell lung cancer.
Sep 1, 2026, 10:17 UTC
Revolution Medicines, Inc. signed four lease agreements for buildings at 1600, 1700, 1800 and 1900 Seaport Boulevard in Redwood City, California, with staggered commencements from September 26, 2027 to September 1, 2028 and initial terms ending September 2042, subject to Phase II Closing by the landlords' acquisition of the properties.
Aug 28, 2026, 17:15 UTC
Revolution Medicines' drug daraxonrasib (brand name Rasonque) was approved by the FDA this week for treating pancreatic cancer with a key mutation.
Source:Aug 10, 2026, 10:00 UTC
BeOne Medicines and Revolution Medicines announced a multi-part collaboration including clinical development and regional commercialization of drug combinations.
Aug 5, 2026, 23:00 UTC
Revolution Medicines, Inc. held its Q2 2026 earnings call on August 5, 2026.
Source:Jul 22, 2026, 20:05 UTC
The U.S. FDA accepted for review Revolution Medicines' New Drug Application for daraxonrasib for previously treated metastatic pancreatic cancer.
Jul 7, 2026, 13:23 UTC
The European Medicines Agency's CHMP started a phased review of Revolution Medicines' investigational drug daraxonrasib.
Source:Jun 24, 2026, 15:16 UTC
Revolution Medicines starts a Phase III clinical trial of zoldonrasib plus chemotherapy for first-line metastatic pancreatic cancer with RAS G12D mutations.
Source:Jun 22, 2026, 12:00 UTC
Revolution Medicines announced that Steve Kelsey will transition from president of R&D to senior advisor to the CEO, ahead of his planned retirement in January 2027, and the company announced a new R&D leadership structure.
Source:Jun 1, 2026, 14:16 UTC
Revolution Medicines released detailed phase III clinical trial results for daraxonrasib in pancreatic cancer, showing a 60% reduction in death risk and doubled median survival.
Source:Jun 1, 2026, 13:26 UTC
Revolution Medicines shares rose 12% in US premarket trading after the release of new clinical data for its experimental pancreatic cancer drug daraxonrasib.
Source:May 30, 2026, 13:25 UTC
Revolution Medicines has started shipping its experimental pancreatic cancer drug daraxonrasib to physicians and patients under an FDA-authorized early access program.